Bone marrow transplantation for the heart: Fact or fiction?

Lancet

Volumn 361, Issue 9351, 2003, Pages 11-12

  Laham, Roger J ^a   Oettgen, Peter ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGINA PECTORIS; ANGIOGENESIS; BONE MARROW TRANSPLANTATION; CELL COMPOSITION; CELL SURVIVAL; CELL TRANSPLANTATION; CORONARY ARTERY BYPASS GRAFT; ELECTROCHEMISTRY; GENE TRANSFER; HEART DISEASE; HEART INFARCTION; HUMAN; MUSCLE DEVELOPMENT; NOTE; PRIORITY JOURNAL; SAFETY;

EID: 0037417515     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12186-1     Document Type: Note

References (12)

1. Laham R.J., Simons M., Sellke F. Gene transfer for angiogenesis in coronary artery disease. Annu Rev Med. 52:2001;485-502.
2. Laham R.J., Chronos N.A., Pike M., et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol. 36:2000;2132-2139.
3. Simons M., Annex B.H., Laham R.J., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 105:2002;788-793.
4. Henry T.D., Rocha-Singh K., Isner J.M., et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J. 142:2001;872-880.
5. Isner J.M., Pieczek A., Schainfeld R., et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in a patient with ischaemic limb. Lancet. 348:1996;370-374.
6. Grines C.L., Watkins M.W., Helmer G., et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 105:2002;1291-1297.
7. Losordo D.W., Vale P.R., Hendel R.C., et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 105:2002;2012-2028.
8. Kocher A.A., Schuster M.D., Szabolcs M.J., et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 7:2001;430-436.
9. Kamihata H., Matsubara H., Nishiue T., et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 104:2001;1046-1052.
10. Ghostine S., Carrion C., Souza L.C., et al. Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation. 106:(suppl 1):2002;I131-I136.
11. Menasche P., Hagege A.A., Scorsin M., et al. Myoblast transplantation for heart failure. Lancet. 357:2001;279-280.
12. Min J.Y., Sullivan M.F., Yang Y., et al. Significant improvement of heart function by cotransplantation of human mesenchymal stem cells and fetal cardiomyocytes in postinfarcted pigs. Ann Thorac Surg. 74:2002;1568-1575.